Centauri Therapeutics, a biotech company based in Cheshire’s Alderley Park, has secured a £30m Series A funding round to support the completion of clinical studies for its antimicrobial treatments.
The drug discovery company, which develops immunotherapy treatments, is working towards the completion of Phase I clinical studies for CTX-187, its lead clinical candiate in the ABX-01 programme focused on combatting drug-resistant bacteria.
Included in the Series A round was a £6m investment from AMR Action Fund, a venture capital fund specifically dedicated to firms in antimicrobial therapeutics and diagnostics research.
“The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options,” said AMR Action Fund chief executive Dr Henry Skinner.
“Centauri’s approach represents a promising opportunity to address this challenge, and we are pleased to support the team as they advance toward first-in-human studies.”
Centauri Therapeutics last year received a £3.8m investment from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
“We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections,” said Centauri Therapeutics chief executive Dr Jennifer Schneider.
“This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset.”
